<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325829</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses.</ArticleTitle><Pagination><StartPage>e1012599</StartPage><MedlinePgn>e1012599</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012599</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012599</ELocationID><Abstract><AbstractText>Emerging and recurrent infectious diseases caused by coronaviruses remain a significant public health concern. Here, we present a targeted approach to elicit antibodies capable of neutralizing SARS-CoV-2 variants and other SARS-related coronaviruses. By introducing amino acid mutations at mutation-prone sites, we engineered glycosylation modifications to the Receptor Binding Domain (RBD) of SARS-CoV-2, thereby exposing more conserved, yet less accessible epitopes. We developed both messenger RNA (mRNA) and recombination subunit vaccines using these engineered-RBDs (M1, M2) and the wild-type RBD as immunogens. The engineered-RBD vaccines elicited robust neutralizing responses against various SARS-CoV-2 variants as well as SARS-CoV and WIV1-CoV, and conferred protection in mice challenged with the XBB.1.16 strain. Furthermore, We highlighted that glycan masking is a decisive factor in antibody binding changes and RBD-conserved antibody response. Additionally, the glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses. Our glycan modification strategy significantly enhances broad-spectrum neutralizing efficacy and cellular immunity, providing valuable insights for the development of vaccines against a wide range of SARS-related coronaviruses.</AbstractText><CopyrightInformation>Copyright: © 2024 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zuxin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunhui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for infectious disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Animal Center, Anhui Medical University, Hefei, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Guoguo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for infectious disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yushan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Huiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Abid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Mengyuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengjun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for infectious disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuanyu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chenguang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital; Southern Medical University, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Ministry of Education, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0004-2196-2556</Identifier><AffiliationInfo><Affiliation>School of Life Science; Advanced Research Institute of Multidisciplinary Science; Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="Y">Polysaccharides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">Severe acute respiratory syndrome-related coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325829</ArticleId><ArticleId IdType="pmc">PMC11460674</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012599</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-24-00653</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Platto S, Xue T, Carafoli E. COVID19: an announced pandemic. Cell Death &amp; Disease. 2020;11(9):799. doi: 10.1038/s41419-020-02995-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-02995-9</ArticleId><ArticleId IdType="pmc">PMC7513903</ArticleId><ArticleId IdType="pubmed">32973152</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al.. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279–86.e8. doi: 10.1016/j.cell.2022.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.12.018</ArticleId><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, et al.. Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. The New England journal of medicine. 2023;388(7):662–4. doi: 10.1056/NEJMc2214314</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214314</ArticleId><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan V, Kane RS. Glycosylation as a tool for rational vaccine design. Biotechnol Bioeng. 2020;117(8):2556–70. doi: 10.1002/bit.27361</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.27361</ArticleId><ArticleId IdType="pubmed">32330286</ArticleId></ArticleIdList></Reference><Reference><Citation>Martina CE, Crowe JE Jr., Meiler J. Glycan masking in vaccine design: Targets, immunogens and applications. Front Immunol. 2023;14:1126034. doi: 10.3389/fimmu.2023.1126034</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1126034</ArticleId><ArticleId IdType="pmc">PMC10076883</ArticleId><ArticleId IdType="pubmed">37033915</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinnakasu R, Sakakibara S, Yamamoto H, Wang PH, Moriyama S, Sax N, et al.. Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. The Journal of experimental medicine. 2021;218(12). doi: 10.1084/jem.20211003</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211003</ArticleId><ArticleId IdType="pmc">PMC8641255</ArticleId><ArticleId IdType="pubmed">34623376</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang HY, Liao HY, Chen X, Wang SW, Cheng CW, Shahed-Al-Mahmud M, et al.. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. Sci Transl Med. 2022;14(639):eabm0899. doi: 10.1126/scitranslmed.abm0899</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm0899</ArticleId><ArticleId IdType="pmc">PMC9802656</ArticleId><ArticleId IdType="pubmed">35230146</ArticleId></ArticleIdList></Reference><Reference><Citation>Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, Cho MW, et al.. How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol. 2010;8(12):e1000571. doi: 10.1371/journal.pbio.1000571</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000571</ArticleId><ArticleId IdType="pmc">PMC3006352</ArticleId><ArticleId IdType="pubmed">21203586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WS, Chen IC, Chen HC, Lee YC, Wu SC. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. Front Immunol. 2021;12:795741. doi: 10.3389/fimmu.2021.795741</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.795741</ArticleId><ArticleId IdType="pmc">PMC8674692</ArticleId><ArticleId IdType="pubmed">34925381</ArticleId></ArticleIdList></Reference><Reference><Citation>An Y, Li S, Jin X, Han JB, Xu K, Xu S, et al.. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerg Microbes Infect. 2022;11(1):1058–71. doi: 10.1080/22221751.2022.2056524</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2056524</ArticleId><ArticleId IdType="pmc">PMC9009945</ArticleId><ArticleId IdType="pubmed">35311493</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al.. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–9. doi: 10.1038/s41586-021-03275-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03275-y</ArticleId><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al.. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–44.e16. doi: 10.1016/j.cell.2022.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.044</ArticleId><ArticleId IdType="pmc">PMC8971115</ArticleId><ArticleId IdType="pubmed">35460644</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol. 2021;18(10):2293–306. doi: 10.1038/s41423-021-00752-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00752-2</ArticleId><ArticleId IdType="pmc">PMC8424621</ArticleId><ArticleId IdType="pubmed">34497376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nature reviews Immunology. 2023;23(3):189–99. doi: 10.1038/s41577-022-00784-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB, et al.. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–7. doi: 10.1038/s41586-020-2852-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2852-1</ArticleId><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Zhu X, He WT, Zhou P, Kaku CI, Capozzola T, et al.. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc Natl Acad Sci U S A. 2022;119(29):e2205784119. doi: 10.1073/pnas.2205784119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2205784119</ArticleId><ArticleId IdType="pmc">PMC9304036</ArticleId><ArticleId IdType="pubmed">35767670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al.. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602. doi: 10.1038/s41586-022-04980-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Li M, Yang Y, Li C, Peng Y, Yang H, et al.. An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus. Chinese Chemical Letters. 2023:109270.</Citation></Reference><Reference><Citation>Cohen AA, van Doremalen N, Greaney AJ, Andersen H, Sharma A, Starr TN, et al.. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. 2022;377(6606):eabq0839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al.. Advances in COVID-19 mRNA vaccine development. Signal transduction and targeted therapy. 2022;7(1):94. doi: 10.1038/s41392-022-00950-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00950-y</ArticleId><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;385(10):946–8. doi: 10.1056/NEJMe2111165</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111165</ArticleId><ArticleId IdType="pmc">PMC8427532</ArticleId><ArticleId IdType="pubmed">34469651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, et al.. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. The New England journal of medicine. 2022;386(22):2097–111. doi: 10.1056/NEJMoa2202261</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2202261</ArticleId><ArticleId IdType="pmc">PMC9127771</ArticleId><ArticleId IdType="pubmed">35507481</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Li B, Li K, Liu Y, Li C, Zheng L, et al.. Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. Sci Adv. 2022;8(7):eabm1418. doi: 10.1126/sciadv.abm1418</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abm1418</ArticleId><ArticleId IdType="pmc">PMC8849333</ArticleId><ArticleId IdType="pubmed">35171673</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al.. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nature communications. 2014;5:4277. doi: 10.1038/ncomms5277</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5277</ArticleId><ArticleId IdType="pmc">PMC4111939</ArticleId><ArticleId IdType="pubmed">24969323</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, et al.. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nature communications. 2023;14(1):2800. doi: 10.1038/s41467-023-38435-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38435-3</ArticleId><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrini G, Magrì D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nat Nanotechnol. 2022;17(6):570–6. doi: 10.1038/s41565-022-01129-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-022-01129-w</ArticleId><ArticleId IdType="pubmed">35710950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al.. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–51. doi: 10.1016/j.jconrel.2015.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.007</ArticleId><ArticleId IdType="pmc">PMC4624045</ArticleId><ArticleId IdType="pubmed">26264835</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al.. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463–76.e6. doi: 10.1016/j.chom.2021.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7869748</ArticleId><ArticleId IdType="pubmed">33592168</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al.. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024–42.e21. doi: 10.1016/j.cell.2020.09.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al.. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–5. doi: 10.1038/s41586-020-2349-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, et al.. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020;53(6):1272–80.e5. doi: 10.1016/j.immuni.2020.10.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7687367</ArticleId><ArticleId IdType="pubmed">33242394</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CY, Lin CW, Tsai TI, Lee CD, Chuang HY, Chen JB, et al.. Influenza A surface glycosylation and vaccine design. Proc Natl Acad Sci U S A. 2017;114(2):280–5. doi: 10.1073/pnas.1617174114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1617174114</ArticleId><ArticleId IdType="pmc">PMC5240703</ArticleId><ArticleId IdType="pubmed">28028222</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra T, Meyer K, Haga Y, Reagan EK, Weissman D, Ray R. Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity. NPJ vaccines. 2023;8(1):42. doi: 10.1038/s41541-023-00635-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-023-00635-9</ArticleId><ArticleId IdType="pmc">PMC10024013</ArticleId><ArticleId IdType="pubmed">36934116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Li Q, Peng P, Zhang Q, Huang Y, Hu J, et al.. Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice. Veterinary microbiology. 2024;294:110108. doi: 10.1016/j.vetmic.2024.110108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2024.110108</ArticleId><ArticleId IdType="pubmed">38729093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Hussain A, Hu B, Yang H, Li C, Guo S, et al.. Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA. Nature communications. 2024;15(1):6463. doi: 10.1038/s41467-024-50752-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-50752-9</ArticleId><ArticleId IdType="pmc">PMC11292028</ArticleId><ArticleId IdType="pubmed">39085241</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol. 2002;76(9):4634–42. doi: 10.1128/jvi.76.9.4634-4642.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.9.4634-4642.2002</ArticleId><ArticleId IdType="pmc">PMC155086</ArticleId><ArticleId IdType="pubmed">11932429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, et al.. A Thermostable mRNA Vaccine against COVID-19. Cell. 2020;182(5):1271–83.e16. doi: 10.1016/j.cell.2020.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7377714</ArticleId><ArticleId IdType="pubmed">32795413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>